Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMAC130)

Drug Name
Inotuzumab ozogamicin Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Acute lymphocytic leukaemia 2B33.3 Approved [2]
Cross-matching ID
TTD Drug ID
DMAC130

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN Not Available [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute lymphoblastic leukaemia
ICD Disease Classification 2A85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8266).
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.